v3.26.1
Schedule of Equity and Non-Controlling Interests (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Equity [Line Items]    
Non-controlling net loss $ (21,245) $ 11,691
Net loss non-controlling interest (21) (90)
Prior period balance (90)  
Ending period balance (111) (90)
Exozyme Technologies Inc [Member]    
Equity [Line Items]    
Non-controlling net loss $ (64) $ (276)
Weighted average non-controlling percentage 32.16% 32.53%
Net loss non-controlling interest $ (21) $ (90)
Prior period balance (90) 7
Removal of prior period balance of Exozyme due to deconsolidation (7)
Stock-based compensation
Ownership change of non-controlling interest
Ending period balance $ (111) $ (90)